What We Do

Turning single human cells into test tubes, we overcome the limitations of canonical biologics screening in multi-well formats.

Applying the same gene library design principles that we use for biosensor development, we create billions of variants of candidate protein therapeutics.

Each cell is assessed with biosensors for the performance of the protein variant it expresses. This approach makes it possible to rapidly engineer the next generation of biologics.

Regulating the Ryanodine Receptor to fight Alzheimer’s Disease.

Building the next generation of biosensing insulin to treat Diabetes.

Building an assay and finding candidate therapeutics for KIF1A-Associated Neurological Disorder (KAND).